[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100601908":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":26,"responsibleParty":127,"collaborators":19,"id":129,"slug":130,"hasResults":131,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":19,"eligibilityCriteria":135,"healthyVolunteers":131,"sex":136,"minAge":137,"maxAge":19,"enrollmentInfo":138,"targetDuration":19,"studyType":141,"phases":142,"briefSummary":145,"conditions":146,"keywords":148,"overallStatus":29,"whyStopped":19,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":162},{"fullName":5,"class":6},"ModernaTX, Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"mRNA-2808","EXPERIMENTAL","Participants will receive mRNA-2808.",[13],"Drug: mRNA-2808",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","intravenous",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Moderna WeCare Team","CONTACT","+1-866-663-3762","WeCareClinicalTrials@modernatx.com",[27,41,51,61,72,81,87,97,107,117],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":19},"University of Alabama at Birmingham Hospital","RECRUITING","Birmingham","Alabama","35233","United States","US",{"type":36,"coordinates":37},"Point",[38,39],-86.80249,33.52066,{"lat":39,"lon":38},{"facility":42,"status":29,"city":43,"state":44,"zip":45,"country":33,"countryCode":34,"cosmosGeoPoint":46,"geoPoint":50,"contacts":19},"UCSF","San Francisco","California","94143",{"type":36,"coordinates":47},[48,49],-122.41942,37.77493,{"lat":49,"lon":48},{"facility":52,"status":29,"city":53,"state":54,"zip":55,"country":33,"countryCode":34,"cosmosGeoPoint":56,"geoPoint":60,"contacts":19},"Emory University Hospital","Atlanta","Georgia","30322",{"type":36,"coordinates":57},[58,59],-84.38798,33.749,{"lat":59,"lon":58},{"facility":62,"status":63,"city":64,"state":65,"zip":66,"country":33,"countryCode":34,"cosmosGeoPoint":67,"geoPoint":71,"contacts":19},"Mass General Brigham","NOT_YET_RECRUITING","Boston","Massachusetts","02114",{"type":36,"coordinates":68},[69,70],-71.05977,42.35843,{"lat":70,"lon":69},{"facility":73,"status":29,"city":74,"state":74,"zip":75,"country":33,"countryCode":34,"cosmosGeoPoint":76,"geoPoint":80,"contacts":19},"Tisch Cancer Institute at Mount Sinai","New York","10029",{"type":36,"coordinates":77},[78,79],-74.00597,40.71427,{"lat":79,"lon":78},{"facility":82,"status":29,"city":74,"state":74,"zip":83,"country":33,"countryCode":34,"cosmosGeoPoint":84,"geoPoint":86,"contacts":19},"Memorial Sloan-Kettering Cancer Center","10065",{"type":36,"coordinates":85},[78,79],{"lat":79,"lon":78},{"facility":88,"status":29,"city":89,"state":90,"zip":91,"country":33,"countryCode":34,"cosmosGeoPoint":92,"geoPoint":96,"contacts":19},"Atrium Health Levine Cancer Institute","Charlotte","North Carolina","28204",{"type":36,"coordinates":93},[94,95],-80.84313,35.22709,{"lat":95,"lon":94},{"facility":98,"status":29,"city":99,"state":100,"zip":101,"country":33,"countryCode":34,"cosmosGeoPoint":102,"geoPoint":106,"contacts":19},"Penn Medicine","Philadelphia","Pennsylvania","19104",{"type":36,"coordinates":103},[104,105],-75.16362,39.95238,{"lat":105,"lon":104},{"facility":108,"status":29,"city":109,"state":110,"zip":111,"country":33,"countryCode":34,"cosmosGeoPoint":112,"geoPoint":116,"contacts":19},"Sarah Cannon Research Institute","Nashville","Tennessee","37203",{"type":36,"coordinates":113},[114,115],-86.78444,36.16589,{"lat":115,"lon":114},{"facility":118,"status":29,"city":119,"state":120,"zip":121,"country":33,"countryCode":34,"cosmosGeoPoint":122,"geoPoint":126,"contacts":19},"The Medical College of Wisconsin","Milwaukee","Wisconsin","53226",{"type":36,"coordinates":123},[124,125],-87.90647,43.0389,{"lat":125,"lon":124},{"type":128,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100601908","phase-1-a-study-of-mrna-2808-in-participants-with-relapsed-or-refractory-multiple-myeloma-100601908",false,"NCT07116616","A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma","A Phase 1\u002F2, Open-label, Multicenter Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma","Key Inclusion Criteria:\n\n* RRMM with prior exposure to a proteasome inhibitor, an immunomodulatory drug (IMiD), and an anti-cluster of differentiation (CD38) monoclonal antibody.\n* Measurable disease defined as at least 1 of the following:\n\n  * Serum M-protein ≥0.5 grams\u002Fdeciliter\n  * Urine M-protein ≥200 milligrams (mg)\u002F24-hour\n  * Involved free light chain (FLC) ≥100 mg\u002Fliter and an abnormal FLC ratio\n  * Plasmacytoma with a single diameter ≥2 centimeters\n  * Bone marrow plasma cells \\>30%\n\nKey Exclusion Criteria:\n\n* Known central nervous system (CNS) myeloma or clinical signs and symptoms of CNS involvement of myeloma.\n* Active plasma cell leukemia, defined as peripheral blood plasma cells ≥20%.\n* Radiotherapy or cytotoxic chemotherapy within 2 weeks prior to Day 1 (Baseline), except palliative radiotherapy of limited field is permissible within 2 weeks after discussion with the Sponsor medical monitor.\n* Antibody-based immunotherapy (monoclonal antibody, bispecific antibody, antibody drug conjugate) within 21 days prior to Day 1 (Baseline).\n* Proteasome inhibitor therapy or immunomodulatory agent within 14 days prior to Day 1 (Baseline).\n* Autologous hematopoietic cell transplant within 100 days prior to Day 1 (Baseline).\n* Allogeneic hematopoietic cell transplant within 180 days prior to Day 1 (Baseline).\n* Genetically modified adoptive autologous or allogeneic cellular therapy (for example, chimeric antigen receptor T cell, chimeric antigen receptor natural killer) within 12 weeks prior to Day 1 (Baseline).\n* Corticosteroid therapy ≥140 mg prednisone or equivalent cumulative dose within 14 days prior to Day 1 (Baseline).\n\nNote: Other inclusion and exclusion criteria may apply.","ALL","18 Years",{"count":139,"type":140},166,"ESTIMATED","INTERVENTIONAL",[143,144],"PHASE1","PHASE2","The purpose of this study is to evaluate the safety and tolerability of mRNA-2808 in participants with relapsed or refractory multiple myeloma (RRMM).",[147],"Relapsed or Refractory Multiple Myeloma",[149,150,151,152],"relapsed or refractory multiple myeloma","RRMM","multiple myeloma","MM","2026-06-25",{"date":155,"type":156},"2026-06-29","ACTUAL",{"date":158,"type":156},"2025-09-30",{"date":160,"type":140},"2032-06-17",{"name":5,"class":6},10]